Genetics & Applications

genapp.ba

Genetics and Applications (G&A) is the official journal of the Institute for Genetic Engineering and Biotechnology, University of Sarajevo. It is envisaged as an international journal issued twice a year in print and online format, publishing peer-reviewed articles of novel and significant discoveries in the fields of basic and applied genetics. Special issues or supplements may also be produced from time to time upon agreement with the Editorial Board.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SEATTLE GENETICS & ASTELLAS REPORT POSITIVE UROTHELIAL CANCER STUDY

Biospace.com | March 28, 2019

news image

Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial. The trial is evaluating enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who had previously received both platinum-based chemotherapy and a checkpoint inhibitor. Enfortumab vedotin is an antibody-drug conjugate (ADC) targeting Nectin-4. Nectin-4 is highly expressed in urothelial cancers, as well as other solid tumors. The drug re...

Read More

AS ADCETRIS SLOWS, SEATTLE GENETICS TOUTS EARLY LAUNCH FIGURES FOR BLADDER CANCER MED PADCEV

FiercePharma | February 07, 2020

news image

It wasn’t long ago when Seattle Genetics shareholders moved past earlier letdowns and cheered strong performance from key cancer drug Adcetris. But now, they might be disappointed again. During the fourth quarter, Adcetris pulled in sales of $166.2 million in the U.S. and Canada, a 26% increase over 2018. Still, the number came below the Street’s expectations of $174.5 million as well as its own third-quarter sales of $167.6 million. The fourth-quarter haul brought the antibody-drug ...

Read More

ADVANCED WIRELESS AND BATTERY-FREE OPTOGENETICS DEVICE TO CONTROL NEURONAL ACTIVATION

Medgadget | January 08, 2019

news image

Researchers at the University of Arizona have developed an advanced optogenetics device that can stimulate multiple areas of the brain at once and control the intensity of emitted light. The miniaturized device is wireless and battery-free, and the researchers hope that it will pave the way to treating severe neurological disorders and controlling chronic pain. Optogenetics involves loading specific neurons with proteins called opsins, which can stimulate a neuron to fire when exposed to light. ...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

SEATTLE GENETICS & ASTELLAS REPORT POSITIVE UROTHELIAL CANCER STUDY

Biospace.com | March 28, 2019

Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial. The trial is evaluating enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who had previously received both platinum-based chemotherapy and a checkpoint inhibitor. Enfortumab vedotin is an antibody-drug conjugate (ADC) targeting Nectin-4. Nectin-4 is highly expressed in urothelial cancers, as well as other solid tumors. The drug re...

Read More
news image

AS ADCETRIS SLOWS, SEATTLE GENETICS TOUTS EARLY LAUNCH FIGURES FOR BLADDER CANCER MED PADCEV

FiercePharma | February 07, 2020

It wasn’t long ago when Seattle Genetics shareholders moved past earlier letdowns and cheered strong performance from key cancer drug Adcetris. But now, they might be disappointed again. During the fourth quarter, Adcetris pulled in sales of $166.2 million in the U.S. and Canada, a 26% increase over 2018. Still, the number came below the Street’s expectations of $174.5 million as well as its own third-quarter sales of $167.6 million. The fourth-quarter haul brought the antibody-drug ...

Read More
news image

ADVANCED WIRELESS AND BATTERY-FREE OPTOGENETICS DEVICE TO CONTROL NEURONAL ACTIVATION

Medgadget | January 08, 2019

Researchers at the University of Arizona have developed an advanced optogenetics device that can stimulate multiple areas of the brain at once and control the intensity of emitted light. The miniaturized device is wireless and battery-free, and the researchers hope that it will pave the way to treating severe neurological disorders and controlling chronic pain. Optogenetics involves loading specific neurons with proteins called opsins, which can stimulate a neuron to fire when exposed to light. ...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More